Key TakeawaysEli Lilly’s experimental obesity treatment retatrutide demonstrated weight reduction of up to 70.3 pounds (28.3% body weight loss) during an 80-week Phase 3 clinical trial.The trial data suggests superior performance compared to Eli Lilly’s existing obesity medications Zepbound and Foundayo when evaluated across separate studies.Approximately 45% of the trial’s 2,500 participants reached 30% or greater weight reduction — a benchmark historically achieved only through surgical intervention.A reduced 4mg dosage demonstrated excellent tolerability, with discontinuation rates lower than those observed in the control group.LLY shares increased approximately 1% during Thursday’s morning session; year-to-date, the stock remains down roughly 5%.Eli Lilly’s pipeline obesity medication has delivered some of the most remarkable clinical outcomes observed in metabolic disease treatment.Eli Lilly and Company, LLYRetatrutide, administered as a once-weekly injectable targeting three distinct gut hormones, successfully completed a pivotal late-stage clinical study announced Thursday. Participants with obesity receiving the maximum 12mg dosage achieved average body weight reduction of 28.3% — approximately 70.3 pounds — throughout the 80-week study period. The 9mg dosage group experienced an average loss of 64.4 pounds.Meanwhile, the control group receiving placebo achieved only 2.2% body weight reduction.LLY stock climbed approximately 1% during Thursday morning hours. Despite this gain, shares remain down about 5.2% for the current year amid growing competition within the GLP-1 therapeutic market.Roughly 45% of the approximately 2,500 study participants achieved total weight loss of 30% or more. This milestone has traditionally only been attainable through surgical weight-loss procedures.Speaking with CNBC, Dan Skovronsky, Lilly’s chief scientific and product officer, characterized 30% weight reduction as “an incredible number to see” within this medication category.Retatrutide Performance Versus Current Market OptionsRetatrutide operates through a distinct mechanism compared to Lilly’s available products. The medication activates receptor sites for three hormones — GLP-1, GIP, and glucagon — versus the two-hormone approach of Zepbound and single-hormone mechanism of earlier GLP-1 treatments.Although cross-trial direct comparisons present methodological challenges, the data points are striking. Zepbound’s maximum dosage delivered approximately 20–22% weight reduction in its registration trial. Foundayo, Lilly’s oral GLP-1 formulation, showed even more modest results.A novel 4mg dosage level evaluated in this study also generated analyst attention. This lower dose achieved 19% weight loss — comparable to high-dose Zepbound — while demonstrating superior tolerability. Only 4% of participants receiving this dosage discontinued due to adverse events, versus nearly 5% in the placebo cohort.The medication’s safety characteristics aligned generally with other GLP-1 class drugs. Gastrointestinal reactions including nausea (42% at maximum dose) and diarrhea (32%) represented the most frequent complaints. No cardiovascular or hepatic concerns emerged, addressing potential risks some analysts had identified related to the drug’s glucagon activity.Lilly reported a moderately elevated incidence of urinary tract infections relative to placebo, though most cases were mild. Skovronsky indicated the UTI occurrence may correlate with the rapidity and magnitude of weight reduction, noting comparable patterns following surgical weight loss.Regulatory Path Forward for RetatrutideThis marks the third successful late-stage outcome for retatrutide. The drug previously demonstrated efficacy in a diabetes study earlier this year and achieved positive results in a smaller December 2025 trial evaluating patients with obesity and osteoarthritis of the knee.TD Cowen analysts project the medication could produce $3.8 billion in annual revenue by 2030, contingent upon regulatory approval.Lilly commands approximately 60% of the GLP-1 market share, according to company data. Novo Nordisk’s Wegovy oral formulation has captured market position in the oral weight-loss category, where Lilly’s Foundayo also operates.Lilly announced its intention to leverage these clinical findings toward submission of a regulatory application for retatrutide.The post Eli Lilly (LLY) Stock Rises as Retatrutide Delivers Unprecedented Weight Loss Results appeared first on Blockonomi.